UB Paderborn / Katalog / Suche / in CDI

1 – 23 von 23

Sortiert nach

Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study

PloS one, 2021-02, Vol.16 (2), p.e0245827-e0245827

2021

Link zum Volltext

Verfügbarkeit prüfen

Correction: Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study

PloS one, 2021-04, Vol.16 (4), p.e0250475-e0250475

2021

Link zum Volltext

Verfügbarkeit prüfen

Tolerability and safety of Octagam® (IVIG): a post-authorization safety analysis of four non-interventional phase IV trials

International journal of clinical pharmacology and therapeutics, 2016-11, Vol.54 (11), p.847

2016

Link zum Volltext

Verfügbarkeit prüfen

Octagam ® for chronic inflammatory demyelinating polyneuropathy: results from three observational studies

Neurodegenerative disease management, 2018-08, Vol.8 (4), p.227-231

Wietek, Stefan

2018

Link zum Volltext

Verfügbarkeit prüfen

AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500 U/1 mL and 500 U/2 mL dilutions

Clinical parkinsonism & related disorders, 2021-01, Vol.5, p.100115-100115, Article 100115

2021

Link zum Volltext

Verfügbarkeit prüfen

Octagam

Neurodegenerative disease management, 2018-08, Vol.8 (4), p.227-231

Wietek, Stefan

2018

Link zum Volltext

Verfügbarkeit prüfen

Development of the Hygiene Extension Limb Position Pain (HELP) tool to monitor waning of clinical efficacy in patients with spasticity or cervical dystonia treated with botulinum toxins

Toxicon (Oxford), 2021-01, Vol.190, p.S57-S57

2021

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of abobotulinumtoxinA in pediatric lower limb spasticity (PLLS): 2nd interim results from a Phase IV, prospective, observational, multicenter study

Toxicon (Oxford), 2021-01, Vol.190, p.S28-S28

2021

Link zum Volltext

Verfügbarkeit prüfen

Tolerability and safety of the intravenous immunoglobulin octagam® 10% in patients with immune thrombocytopenia: a post-authorisation safety analysis of two non-interventional phase IV trials

Hematology (Luxembourg), 2018-04, Vol.23 (4), p.242-247

2018

Link zum Volltext

Verfügbarkeit prüfen

AbobotulinumtoxinA using 2-mL dilution (500 U/2-mL) maintains durable improvement across multiple treatment cycles

Journal of Clinical Movement Disorders (Online), 2020-08, Vol.7 (1), p.8-8, Article 8

2020

Link zum Volltext

Verfügbarkeit prüfen

Predicting therapeutic efficacy of intravenous immunoglobulin (IVIG) in individual patients with relapsing remitting multiple sclerosis (RRMS) by functional genomics

Journal of neuroimmunology, 2014-12, Vol.277 (1), p.145-152

2014

Link zum Volltext

Verfügbarkeit prüfen

A randomized, double-blind, placebo-controlled dose-finding trial of intravenous immunoglobulin (IVIG; Octagam® 10%, Octapharma AG) in patients with mild to moderate Alzheimer's disease (GAM10-04)

Alzheimer's & dementia, 2011-07, Vol.7 (4), p.e55-e56

2011

Link zum Volltext

Verfügbarkeit prüfen

P4‐411: A randomized, double‐blind, placebo‐controlled dose‐finding trial of intravenous immunoglobulin (IVIG; Octagam® 10%, Octapharma AG) in patients with mild to moderate Alzheimer's disease (GAM10‐04)

Alzheimer's & dementia, 2011-07, Vol.7 (4S_Part_25), p.e55-e56

2011

Link zum Volltext

Verfügbarkeit prüfen

P3‐283: Randomized double‐blind placebo‐controlled dose‐finding trial of intravenous immunoglobulin (octagam® 10%, octapharma AG) in patients with Alzheimer's disease

Alzheimer's & dementia, 2010-07, Vol.6 (4S_Part_17), p.S534-S534

2010

Link zum Volltext

Verfügbarkeit prüfen

Randomized double-blind placebo-controlled dose-finding trial of intravenous immunoglobulin (octagam® 10%, octapharma AG) in patients with Alzheimer's disease

Alzheimer's & dementia, 2010-07, Vol.6 (4), p.S534-S534

2010

Link zum Volltext

Verfügbarkeit prüfen

Brain glucose metabolism in patients with mild to moderate Alzheimer's disease before and after six months treatment with intravenous immunoglobulin (octagam 10%): A phase II double blind, placebo-controlled multi-center study

Alzheimer's & dementia, 2011-07, Vol.7 (4), p.e39-e39

2011

Link zum Volltext

Verfügbarkeit prüfen

P4‐362: Brain glucose metabolism in patients with mild to moderate Alzheimer's disease before and after six months treatment with intravenous immunoglobulin (octagam 10%): A phase II double blind, placebo‐controlled multi‐center study

Alzheimer's & dementia, 2011-07, Vol.7 (4S_Part_24), p.e39-e39

2011

Link zum Volltext

Verfügbarkeit prüfen

Non-antisense cellular responses to oligonucleotides

FEBS letters, 2002-01, Vol.510 (3), p.175-180

2002

Link zum Volltext

Verfügbarkeit prüfen

Experimental Regulation of STAT Gene Expression Reveals an Involvement of STAT5 in Interleukin-4-Driven Cell Proliferation

Biological chemistry, 2001-02, Vol.382 (2), p.343-351

2001

Link zum Volltext

Verfügbarkeit prüfen

A Two-Step Selection Approach for the Identification of Ligand-Binding Determinants in Cytokine Receptors

Analytical biochemistry, 1999-03, Vol.268 (2), p.179-186

1999

Link zum Volltext

Verfügbarkeit prüfen

Unifying photocycle model for light adaptation and temporal evolution of cation conductance in channelrhodopsin-2

Proceedings of the National Academy of Sciences - PNAS, 2019-05, Vol.116 (19), p.9380-9389

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(23)

Sprache

Englisch
(23)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(11)
Life Sciences & Biomedicine
(9)
Humans
(7)
Neurology
(6)
Intravenous Immunoglobulin
(4)
Neurosciences & Neurology
(4)
Tolerability
(4)
Aged
(3)
Aged, 80 And Over
(3)
Animals
(3)
Biochemistry & Molecular Biology
(3)
Clinical Neurology
(3)
Clinical Trials
(3)
Female
(3)
Immunoglobulins, Intravenous - Adverse Effects
(3)
Ivig
(3)
Male
(3)
Middle Aged
(3)
Adolescent
(2)
Adult
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Alzheimer's & Dementia
(6)
Lancet Neurology
(2)
Neurodegenerative Disease Management
(2)
Plos One
(2)
Toxicon
(2)
Analytical Biochemistry
(1)
Biological Chemistry
(1)
Clinical Parkinsonism & Related Disorders
(1)
Febs Letters
(1)
Hematology
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study

Correction: Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study

Tolerability and safety of Octagam® (IVIG): a post-authorization safety analysis of four non-interventional phase IV trials

Octagam ® for chronic inflammatory demyelinating polyneuropathy: results from three observational studies

AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500 U/1 mL and 500 U/2 mL dilutions

Octagam

Development of the Hygiene Extension Limb Position Pain (HELP) tool to monitor waning of clinical efficacy in patients with spasticity or cervical dystonia treated with botulinum toxins

Efficacy and safety of abobotulinumtoxinA in pediatric lower limb spasticity (PLLS): 2nd interim results from a Phase IV, prospective, observational, multicenter study

Tolerability and safety of the intravenous immunoglobulin octagam® 10% in patients with immune thrombocytopenia: a post-authorisation safety analysis of two non-interventional phase IV trials

AbobotulinumtoxinA using 2-mL dilution (500 U/2-mL) maintains durable improvement across multiple treatment cycles

Predicting therapeutic efficacy of intravenous immunoglobulin (IVIG) in individual patients with relapsing remitting multiple sclerosis (RRMS) by functional genomics

Intravenous immunoglobulins for the treatment of mild to moderate Alzheimer’s disease: a phase II, randomised, double-blind, placebo-controlled dose-finding trial

A randomized, double-blind, placebo-controlled dose-finding trial of intravenous immunoglobulin (IVIG; Octagam® 10%, Octapharma AG) in patients with mild to moderate Alzheimer's disease (GAM10-04)

P4‐411: A randomized, double‐blind, placebo‐controlled dose‐finding trial of intravenous immunoglobulin (IVIG; Octagam® 10%, Octapharma AG) in patients with mild to moderate Alzheimer's disease (GAM10‐04)

P3‐283: Randomized double‐blind placebo‐controlled dose‐finding trial of intravenous immunoglobulin (octagam® 10%, octapharma AG) in patients with Alzheimer's disease

Randomized double-blind placebo-controlled dose-finding trial of intravenous immunoglobulin (octagam® 10%, octapharma AG) in patients with Alzheimer's disease

Brain glucose metabolism in patients with mild to moderate Alzheimer's disease before and after six months treatment with intravenous immunoglobulin (octagam 10%): A phase II double blind, placebo-controlled multi-center study

P4‐362: Brain glucose metabolism in patients with mild to moderate Alzheimer's disease before and after six months treatment with intravenous immunoglobulin (octagam 10%): A phase II double blind, placebo‐controlled multi‐center study

Non-antisense cellular responses to oligonucleotides

Experimental Regulation of STAT Gene Expression Reveals an Involvement of STAT5 in Interleukin-4-Driven Cell Proliferation

A Two-Step Selection Approach for the Identification of Ligand-Binding Determinants in Cytokine Receptors

Unifying photocycle model for light adaptation and temporal evolution of cation conductance in channelrhodopsin-2

Suchergebnisse filtern